Observational studyMedicine2025
Analysis of factors affecting the efficacy of contralateral seventh cervical nerve transfer for central upper limb paralysis and prediction model for efficacy evaluation.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to evaluate the efficacy, safety, and predictors of contralateral C7 nerve transfer (CC7) for central upper limb spastic hemiplegia and develop a preoperative prediction model. A retrospective analysis included 58 stroke patients with spastic hemiplegia undergoing CC7 surgery. Composite efficacy endpoints assessed efficacy. Univariate and multivariate logistic regression identified predictive factors. A nomogram prediction model was built and validated using receiver operating characteristic curves, calibration curves, and decision curve analysis. CC7 significantly improved affected upper limb function. The Fugl-Meyer Assessment for upper extremity (FMA-UE) score increased from 25.9 ± 3.6 preoperatively to 37.6 ± 3.4 at final follow-up (P < .001). Based on composite endpoints, the overall efficacy rate was 60.3% (35/58). Analysis of 15 potential factors identified 2 significant independent predictors of efficacy: younger age (odds ratio = 0.86, 95% confidence interval [CI]: 0.77-0.96, P = .006) and higher baseline FMA-UE score (odds ratio = 1.45, 95% CI: 1.12-1.89, P = .005). A nomogram incorporating these factors demonstrated strong diagnostic performance (area under the curve = 0.898, 95% CI: 0.820-0.976, P < .05). Bootstrap validation (area under the curve = 0.884), calibration curves, and decision curve analysis confirmed the model's robustness and clinical utility. CC7 showed good safety; postoperative adverse reactions (transient contralateral limb numbness/pain) were mild and resolved without long-term issues. CC7 is a safe and effective treatment for central hemiplegia, significantly improving upper limb function. The developed nomogram, using age and baseline FMA-UE score, provides an accurate tool for predicting CC7 efficacy and aiding patient selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.